Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.98 +0.25 (+0.46%)
Streaming Delayed Price Updated: 1:17 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
2 Growth Stocks to Stash and 1 We Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
News headline image
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation ↗
BioMarin Pharmaceutical (BMRN) is a top value investing pick, trading at a discount with strong financial health, high profitability, and solid growth potential. 
Via Chartmill
News headline image
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around BioMarin Pharmaceutical? ↗
 
Via Benzinga
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
2 Reasons to Watch BMRN and 1 to Stay Cautious
Over the past six months, BioMarin Pharmaceutical’s stock price fell to $57. Shareholders have lost 17.1% of their capital, which is disappointing considering the S&P 500 has climbed by 4.7%. This may... 
Via StockStory
Topics Stocks
News headline image
Predicting the Next Rule Breaker Buyout ↗
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter ↗
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise. 
Via Benzinga
Topics Stocks
News headline image
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential ↗
Value investing highlights undervalued stocks like BioMarin Pharmaceutical, with strong financials, earnings, and growth potential, offering a margin of safety. 
Via Chartmill
News headline image
BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
News headline image
Is BioMarin Pharmaceutical Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 ↗
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth. 
Via Benzinga
News headline image
BioMarin (BMRN) Q2 Revenue Jumps 16% ↗
Via The Motley Fool
Topics Economy
News headline image
BioMarin (BMRN) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
News headline image
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Exceeds Q2 2025 Earnings Expectations, Shares Climb After Hours ↗
BioMarin Pharmaceutical beats Q2 2025 estimates with $825.4M revenue, EPS of $1.44, and raises full-year guidance. Stock surges 4.6% post-earnings. 
Via Chartmill
News headline image
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings this Monday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
What's Next: Biomarin Pharmaceutical's Earnings Preview ↗
 
Via Benzinga
News headline image
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics ↗
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact. 
Via Benzinga
News headline image
1 Mid-Cap Stock Worth Investigating and 2 We Turn Down
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
What Does the Market Think About BioMarin Pharmaceutical? ↗
 
Via Benzinga
News headline image
Demystifying BioMarin Pharmaceutical: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 We Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock Worth Watching ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) shows strong profitability, solid financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector. 
Via Chartmill
News headline image
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money ↗
Three magnificent businesses with well-defined catalysts can deliver triple-digit returns amid a historically pricey stock market. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) – An Undervalued Biotech Stock With Strong Fundamentals ↗
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.